Samenvatting
Background Exercise parameters are not routinely incorporated in decision making for cardiac resynchronisation therapy (CRT). Submaximal exercise parameters better reflect daily functional capacity of heart failure patients than parameters measured at maximal exertion, and may therefore better predict response to CRT. We compared various exercise parameters, and sought to establish which best predict CRT response. Methods In 31 patients with chronic heart failure (61% male; age 68±7 years), submaximal and maximal cycling testing was performed before and 3 months after CRT. Submaximal oxygen onset (τVO 2 onset) and recovery kinetics (τVO 2 recovery), peak oxygen uptake (VO 2 peak) and oxygen uptake efficiency slope (OUES) where measured. Response was defined as ≥15% relative reduction in end-systolic volume. Results After controlling for age, New York Heart Association and VO 2 peak, fast submaximal VO 2 kinetics were significantly associated with response to CRT, measured either during onset or recovery of submaximal exercise (area under the curve, AUC=0.719 for both; p<0.05). By contrast, VO 2 peak (AUC=0.632; p=0.199) and OUES (AUC=0.577; p=0.469) were not associated with response. Among patients with fast onset and recovery kinetics, below 60 s, a significantly higher percentage of responders was observed (91% and 92% vs 43% and 40%, respectively). Conclusions Impaired VO 2 kinetics may serve as an objective marker of submaximal exercise capacity that is age-independently associated with non-response following CRT, whereas maximal exercise parameters are not. Assessment of VO 2 kinetics is feasible and easy to perform, but larger studies should confirm their clinical utility.
Originele taal-2 | Engels |
---|---|
Artikelnummer | e002047 |
Aantal pagina's | 8 |
Tijdschrift | Open Heart |
Volume | 9 |
Nummer van het tijdschrift | 2 |
DOI's | |
Status | Gepubliceerd - 14 nov. 2022 |
Bibliografische nota
Funding Information:This study was supported by a research grant from Medtronic Trading NL B.V., Eindhoven, the Netherlands.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Financiering
This study was supported by a research grant from Medtronic Trading NL B.V., Eindhoven, the Netherlands.